[c09aa8]: / clusters / 9knumclustersv2 / clust_167.txt

Download this file

167 lines (166 with data), 23.1 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
No history of psychiatric disorders that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder) or prevent the patient from giving informed consent
Patient must not have an antecedent hematologic disorder
Known prior history of mania or major psychiatric illness (schizophrenia, bipolar disorder, severe major depression requiring hospitalization, etc.)
Patients with a genetic disorder of fat metabolism
Patients with an identified familial hyperlipidemia disorder
History of idiopathic seizure disorder schizophrenia, or psychosis unrelated to glioblastoma, corticosteroid, or anti-epileptic medications.
Diagnosis of bipolar disorder, schizophrenia, post-traumatic stress disorder (PTSD) and or adult attention deficit hyperactivity disorder (ADHD)
Generalized Anxiety Disorder (GAD)- scale of or higher
Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, could interfere with study assessments or compliance.
Patients with severe psychiatric (i.e. schizophrenia, bipolar, or borderline personality disorder) or other clinically progressive major medical problems, unless approved by the Investigator.
Patients with severe psychiatric (i.e. schizophrenia, bipolar, or borderline personality disorder) or other clinically progressive major medical problems, unless approved by the PI.
Presence of active neurological disorder(s).
Has history of bipolar disorder or major depression
Underlying psychiatric disorder requiring pharmacological intervention or a Hospital Anxiety and Depression Scale (HADS) score of or more
Bipolar disorder
Breast cancer survivors with a severe current psychiatric diagnosis (e.g. bipolar disorder)
Current diagnosed neurologic disorder
Any psychiatric disorder that prohibits obtaining informed consent
The patient has a history of uncontrolled hereditary or acquired thrombotic disorder
Known mania-associated psychiatric disorder
Histologically confirmed histiocytic disorder or histologic findings compatible with a histiocytic disorder in the context of confirmatory radiologic findings
History of clinically significant liver disease, urea cycle disorder, or genetic liver problem caused by a mitochondrial disorder (e.g., Alpers-Huttenlocher syndrome)
Participants with prior documented antecedent hematological disorder (AHD)
Currently taking selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitors (SNRI), or tricyclic antidepressant (TCA) regimen for treatment of major depressive disorder or generalized anxiety disorder (without approval and involvement of the patients treating psychiatrist)
Known malabsorptive disorder
Contraindications to use of bupropion (i.e., concurrent use of other forms of bupropion, MAO inhibitors, anti-depressant medication, seizure disorder or any clinical situation that might increase risk for seizures, past head injury, current or prior diagnosis of bulimia or anorexia nervosa; bipolar disorder).
History of bipolar disorder.
Known diagnosis of bipolar depression or psychosis
Patient has a Generalized Anxiety Disorder (GAD)- mood scale score >=
Patients with a history of a psychiatric disorder that may interfere with the understanding and compliance with this protocol and the required follow up
Patients with a known coagulation disorder are excluded; patients with a first-degree relative with a history of venous thrombosis before age years (yrs) or an arterial thrombosis before age yrs must have the following testing performed prior to enrollment to exclude a heritable disorder; patients with a suspected disorder will be excluded
History of psychiatric disorder (e.g. depression)
Thrombocytopenia secondary to other possible causes, including medication(s), congenital disorder(s), immune disorder(s), or microvascular disorder(s)
Severe psychological illness such as major psychosis (e.g. schizophrenia), major bipolar depression, or suicidal situational depression
Have a history of uncontrolled hereditary or acquired thrombotic disorder.
History of Wilsons disease or other copper-metabolism disorder
Has a known blood clotting disorder requiring treatment
Has uncontrolled disease-related metabolic disorder
Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV diagnoses for psychotic disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), major depressive disorder within the last months, substance dependence within the last months with the exception of nicotine and marijuana dependence
Current major depression or another major psychiatric disorder as described in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-) (use of central nervous system [CNS] active medications (e.g. antidepressants) will be permitted, provided dosing has been stable for at least months)
Patient has a Generalized Anxiety Disorder (GAD)- mood scale score >=
Having a history or presence of a significant psychiatric disorder or any other condition that, in the investigators judgment, would interfere with participation in the trial
History of bipolar disorder
History of eating disorder such as anorexia or bulimia
History of Wilson's disease or other copper-metabolism disorder
Antecedent hematological disorder (AHD)
No medical disorder that increases risks of radiation or temozolomide (TMZ) chemotherapy; no uncontrolled infection; no known positivity for human immunodeficiency virus (HIV); no other disorder limiting expected survival to < years
History of major psychiatric disorder including use of anti-depressive medications, mood stabilizers, or anti-psychotic drugs
Has known psychiatric disorder that would interfere with fulfilling the requirements of the study
Active joint inflammation or history of inflammatory arthritis or other immune disorder involving joints
Previous diagnosis of bipolar disorder
Uncooperative patients, or patients who are incapable of following directions (for example, as a consequence of a neurological or psychiatric disorder).
History of Wilson's disease or other copper-related metabolic disorder
Uncontrolled depression or other major psychiatric disorder
PART I: Participants with evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study will not be allowed to participate
PART II: Participants with evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study will not be allowed to participate
Active joint inflammation or history of inflammatory arthritis or other immune disorder involving the joints
Mentally incapacitated or has a significant emotional or psychiatric disorder
Lifetime history of any DSM-IV-TR mood or psychotic disorder (e.g., major depressive disorder, bipolar disorder, schizophrenia)
Current unstable major medical disorder
Myeloproliferative disorder (MPD)
Have a known major sleep disorder documented by prior diagnosis, such as: a) sleep disordered breathing b) narcolepsy c) periodic limb movement disorder d) parasomnias
History of Wilson's disease or other copper-related metabolic disorder
Patient has a General Anxiety Disorder (GAD)- mood scale score >=
Diagnosis of depression, major depressive disorder (MDD), suicidal ideations or anxiety disorders in the past years per the medical chart based on Diagnostic and Statistical Manual (DSM) IV diagnoses
Patients with active bipolar disorder
History of or currently taking medications for attention deficit hyperactivity disorder, severe anxiety disorder, schizophrenia, or substance abuse by patient record and/or self-report
No active untreated clinically significant psychiatric condition (psychosis, bipolar disorder, or depression)
Major psychiatric disorder, such as schizophrenia, bipolar disorder, or untreated depression (treatment for depression is defined as current therapy with antidepressant medication or cognitive behavioral therapy [CBT])
Participants with a documented history of genetic predisposition for thrombosis (anti-phospholipid antibody syndrome, antithrombin [AT]-III deficiency, etc.), platelet disorder or bleeding disorder
History of major psychiatric condition (e.g. psychosis) in parent or child; severe neurodevelopmental disorder in child (e.g. Down's syndrome)
Have an active serious mental illness (e.g., schizophrenia, bipolar disorder) as indicated by medical records
Major mental illness (e.g., schizophrenia, psychotic disorder)
Serious accompanying cardiac disorder
Serious accompanying cardiac disorder.
No history of mood disorder
History of bipolar disorder diagnosis
Current diagnosis of a major psychiatric disorder (e.g., schizophrenia, bipolar disorder)
History of eating disorder (ever uncontrolled or any within the last two years)
Meet Diagnostic and Statistical Manual of Mental Disorders- (DSM-V) criteria for current major psychiatric illness, such as bipolar disorder, major depression, active suicidal intent, or psychosis that could be exacerbated by the administration of cannabis
Subjects with a history of substance use disorder other than nicotine, such an opiate use disorder
Psychiatric (untreated or poorly controlled schizophrenia, major depression, or bipolar disorder), or communication (language) barrier that would preclude accurate assessment of postoperative pain and/or ability to answer questionnaires (need to be able to read, comprehend, and answer questions)
History of bipolar disorder or manic episodes (which is a contra-indication for light treatment)
Documented attention deficit hyperactivity disorder (ADHD) predating cancer diagnosis
Any of the following: diagnosis of schizophrenia or bipolar disorder made by a physician, seizure disorder, pacemaker, hearing aids, any metal implanted in the head, or the presence of other known current untreated causes of fatigue such as anemia (defined as hemoglobin [Hgb] < g/dL within months of study enrollment) or untreated hypothyroidism
A significant anxiety disorder
Patients who have a cognitive disorder which impacts the ability to follow directions or adhere to safety rules; this will be determined by the physical therapist by assessing whether a neurological disorder or musculoskeletal disorder would prevent the patient from safely exercising
Patients who have a neurological or structural disorder which would impact use of exercise equipment; this will be determined by the physical therapist by assessing whether a neurological disorder or musculoskeletal disorder would prevent the patient from safely exercising
Significant uncontrolled psychiatric disorder (e.g. psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (e.g. dementia, cognitive impairment) which the treating clinician believes prohibits informed consent or participation in the study
Survivors who report ever being diagnosed with bipolar disorder will be excluded
Participants with a history of treated or untreated schizophrenia or bipolar disorder as assessed by self-report and review of medical history
As per self report or as documented in the medical record, current untreated (e.g. no medication, no therapy) major psychiatric disorder (schizophrenia, major depression); patients diagnosed with a major psychiatric disorder will be reviewed by the study principal investigator (PI) to determine eligibility prior to consent
Major mental illness (e.g., schizophrenia, major depressive disorder)
As per self-report, a lifetime history of bipolar disorder, schizophrenia, or schizoaffective disorder
Patients who have ever been diagnosed with bipolar disorder or schizophrenia
Major mental illness (e.g., schizophrenia, major depressive disorder)
Significant physiological or psychological impairment that interferes with participation (e.g., migraines, bipolar disorder, psychosis, seasonal affective disorder)
Neurologic disorder that impairs ambulation (e.g. Parkinsons)
Patients who have any major psychiatric diagnoses or thought disorder (e.g. schizophrenia, bi-polar disorder, dementia)
Has a Diagnostic and Statistical Manual (DSM) IV diagnosis of Major Depressive Disorder
Substance use disorder within the prior six months
Patients who have ever been diagnosed with bipolar disorder or schizophrenia.
Psychiatric disorder such as severe depression, manic depressive disorder, obsessive compulsive disorder or schizophrenia; (defined per medical history)
Have schizophrenia or any other psychotic disorder
Have a diagnosed sleep disorder including untreated obstructive sleep apnea, periodic limb movement disorder, or restless leg syndrome
Diagnosis of a formal thought disorder (e.g., schizophrenia)
A principal diagnosis of major depressive disorder (MDD)
History of bipolar affective disorder or psychosis
Medical history of cancer other than colorectal cancer or non-melanoma skin cancer, untreated or unstable mental or psychiatric disorder, learning disability, traumatic brain injury, drug or alcohol abuse, debilitating medical disorder such as advanced cardiac, respiratory or renal disease
Psychiatric disorders or conditions that would preclude participation in the study intervention (e.g., untreated major depression or psychosis, substance abuse, severe personality disorder)
Serious psychiatric disease including schizophrenia, bipolar disorder and severe depression
Patients must not have any contraindicated concurrent illnesses listed on the duloxetine package insert including:\r\n* Current primary psychiatric diagnosis (schizophrenia, psychosis) or suicidal ideation, history of bipolar disorder, or seizure disorder\r\n* History of alcohol or other substance abuse or dependence within days prior to registration\r\n* Chronic liver disease\r\n* End-stage renal disease\r\n* Uncontrolled narrow-angle glaucoma\r\n* Clinically significant coagulation disorder
Major psychiatric disorder (e.g., psychosis, personality disorder)
Patients who have significant personality disorders or unstable psychiatric disorders (including active major depression, substance abuse, psychosis or bipolar disorder) as assessed by the interviewing clinician
Personal history of an eating disorder
Major mental illness (e.g, schizophrenia, major depressive disorder)
Patients who have any major psychiatric diagnoses (e.g., schizophrenia, bipolar disorder)
Significant uncontrolled psychiatric disorder (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (dementia, cognitive impairment), which the treating clinician believes prohibits the ability to participate in study procedures
Psychiatric disorders or conditions that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, substance abuse, severe personality disorder)
Diagnosis of a major depressive episode, an acute anxiety disorder, psychosis, post-traumatic stress disorder (PTSD), or schizophrenia as listed in the patients medical history per Diagnostic and Statistical Manual of Mental Disorders, th edition (DSM-IV) criteria in the chart and/or by self-report; assessing the concomitant medications will provide some insight into whether this needs further evaluation
Documented history of mental incapacitation or significant emotional or psychiatric disorder (i.e. bipolar, schizophrenia) that, in the opinion of the investigator, precludes study entry as these patients may not be able to cooperate with this slightly invasive procedure or with the data collection process
Co-morbid delirium, dementia, or active and untreated psychotic, bipolar or substance-dependence disorder interfering with consent
History of neurological/psychiatric disorder, including psychotic disorder or dementia, or any other reason, which in the opinion of the investigator makes adherence to a treatment or follow-up schedule unlikely
Significant uncontrolled psychiatric disorder (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (dementia, cognitive impairment), which the treating clinician believes prohibits informed consent or participation in the study
Subject has previously been diagnosed with a serious immunodeficiency disorder.
Patients with an identified familial hyperlipidemia disorder.
Diagnosis of a formal thought disorder (e.g., schizophrenia)
Current or past diagnosis of a major psychiatric disorder precluding adequate outcome responses such as schizophrenia, dementia, delirium etc. as recorded in the pre-operative record
Participant has current major psychiatric illness (i.e. schizophrenia, bipolar disorder)
Currently with a diagnosis of major depression, manic depressive disorder, obsessive-compulsive disorder, or schizophrenia)
Currently with a diagnosis of major depression, manic depressive disorder, obsessive-compulsive disorder, or schizophrenia
Having untreated clinical depression and other psychotic mental disorders (e.g., bipolar, schizophrenia) (>= on the Center for Epidemiological Studies Depression Scale [CES-D])
Major mental illness (e.g., schizophrenia, psychotic disorder)
Diagnosis of psychiatric disorders of psychosis, schizophrenia, or bipolar disorder
Previous diagnosis of radiosensitivity disorder (i.e., ataxia telangiectasia)
Presence or recent history of any systemic disorder or conditions, such as:
Patients will be between months and -years post radiation treatment; ongoing chemoprevention therapy is permissible; based on International Classification of Diseases (ICD)- proposed criteria, a diagnosis of CRF will require evidence from the history, physical exam, and laboratory findings that the fatigue is a consequence of cancer or cancer therapy and not primarily a consequence of comorbid psychiatric disorders (schizophrenia, depression, generalized anxiety disorder, bipolar disorder, dementia, delirium or obsessivecompulsive disorder [OCD])
Educational, psychiatric (untreated or poorly controlled schizophrenia, major depression, or bipolar disorder), or communication (language) barrier that would preclude accurate assessment of postoperative pain and/or ability to answer questionnaires (need to be able to read, comprehend, and answer questions)
Currently in treatment for a major psychiatric disorder
History of demyelinating disorder
Patients must not have a serious psychiatric illness (e.g. lifetime bipolar disorder, schizophrenia or other psychosis, serious personality disorder, severe major depressive disorder or recent suicide or psychiatric hospitalization) (previous months), or a history of an eating disorder (anorexia nervosa or bulimia nervosa)
Any neurologic or psychiatric disorder
Any neurologic or psychiatric disorder except depression, anxiety, or attention-deficit disorder/attention-deficit hyperactivity disorder
History of disordered eating as indicated by the Eating Disorder Examination Questionnaire (EDEQ)
Any serious or unstable medical/psychiatric disorder (including severe substance use disorders, other than tobacco use disorder) in the past month that may interfere with study performance based on principal investigator (PI) judgment
Major depressive disorder in the last year requiring treatment
History of panic disorder, psychosis, bipolar disorder, or eating disorders
Patients with serious, concomitant disorder, including active systemic infection, autoimmune disease, proven or suspected immunosuppressive disorder or any other major medical illnesses of the cardiovascular or respiratory system, concurrent malignancy except for nonmelanoma skin lesions
Unstable medical conditions (such as unstable heart disease, uncontrolled hypertension, thyroid disease, diabetes, renal or liver impairment, glaucoma, or prostatic hypertrophy) or psychiatric condition (such as current major depression, history of schizophrenia or bipolar disorder, or current regular use of psychiatric medications such as major tranquilizers and antidepressants
Have current psychiatric disorders (i.e. major depression, bipolar, and/or psychotic disorders) or substance use disorder as determined by a psychiatric screener (Mini International Neuropsychiatric Interview [MINI])\r\n* Alcohol use disorder: current mild disorder is eligible; moderate disorder is eligible if in early remission (- months); severe disorder, current or early remission, is not eligible\r\n* Substance use disorder is as follows: current disorder is not eligible; mild or moderate in early remission is eligible; severe disorder in early remission is not eligible
Is mentally incapacitated or has a significant emotional or psychiatric disorder
Suffering from a severe psychiatric disorder (assessed using self-reporting history of psychiatric diagnosis during the phone screening) that would interfere with participation
Major depressive disorder in the last year requiring treatment
History of panic disorder, psychosis, bipolar disorder, or eating disorders
Meets Mini International Neuropsychiatric interview (MINI) criteria for major depression, schizophrenia, bipolar illness, delirium or psychosis
With current diagnosis of major axis I psychiatric disorder (Diagnostic and Statistical Manual of Mental Disorders [DSM]-IV), major depression, bipolar disorder, or schizophrenia, as per medical records or patient report
Subject has an acute psychiatric disorder or is cognitively impaired
Current or past major psychiatric illness (e.g., schizophrenia, bipolar affective disorder)
Preexisting language or developmental disorder that would limit ability to cooperate with testing (as determined by the P.I. or treating physician after interviewing potential subject and his/her family; for example, a child may be excluded if he/she has confirmed or suspected autism spectrum disorder, dysarthria, dyslexia, lisp, hypotonia, or other age inappropriate speech development)
Any known psychiatric disorder other than mild depression or anxiety that may affect adherence to the study requirements.
Active or history of major psychiatric disorders such as schizophrenia, schizoaffective disorder, major affective disorder in mid-life, or treatment with electroconvulsive therapy (ECT) (mild depression that is well treated with stable dose of selective serotonin reuptake inhibitor [SSRI] antidepressants may be allowed)
Acute painful perianal disorder
Contraindications to TRUS/prostate biopsy (BX)\r\n* Currently on blood thinning agents (Plavix, Coumadin etc.) or bleeding disorder\r\n* Active urinary tract infection\r\n* Acute painful perianal disorder (i.e. rectal abscess)
Having a history or presence of a significant psychiatric disorder or any other condition that, in the investigators judgment, would interfere with participation in the trial
Patients suffering from a severe psychiatric disorder or condition that would significantly interfere with study participation
PATIENTS: Significant uncontrolled psychiatric disorder (psychotic disorder, bipolar disorder, major depression) or other co-morbid disease (dementia, cognitive impairment), which the treating clinician believes prohibits the ability to participate in study procedures